-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea Therapeutics reports confirmed partial response in Phase 1 APR-1051 cancer trial

PUBT·11/20/2026 14:03:36
Listen to the news
Aprea Therapeutics reports confirmed partial response in Phase 1 APR-1051 cancer trial
  • Aprea Therapeutics announced interim Phase 1 results for WEE1 inhibitor APR-1051, scheduled for presentation today at the EORTC-NCI-AACR symposium in Barcelona.
  • Partial tumor responses emerged in patients with PPP2R1A-mutated uterine cancers; one confirmed response remained ongoing beyond 10 months.
  • The safety profile supported continued dose optimization, though serious lung inflammation and reduced neutrophil counts were reported.
  • Planned expansion targets at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing, platinum-resistant ovarian cancer.
  • Dose escalation and backfill expansion enrollment are expected to finish in the second quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200900PRIMZONEFULLFEED9881831) on November 20, 2026, and is solely responsible for the information contained therein.